<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37462126</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">0048-7449</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>17</Day></PubDate></JournalIssue><Title>Reumatismo</Title><ISOAbbreviation>Reumatismo</ISOAbbreviation></Journal><ArticleTitle>Macrophage activation syndrome in a patient with systemic lupus erythematosus undergoing cyclophosphamide treatment: a case report.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.4081/reumatismo.2023.1597</ELocationID><Abstract><AbstractText>Macrophage activation syndrome (MAS) is a disorder related to hemophagocytic lymphohistiocytosis and is a life-threatening complication of rheumatic diseases. The diagnosis is challenging because MAS symptoms are quite similar to those of many active autoimmune diseases or severe sepsis. We describe the case of a female patient with systemic lupus erythematosus that presented with symptoms suggesting acute decompensation of autoimmune disease and sepsis. She was later diagnosed with MAS. Despite an aggressive immunosuppressive treatment, she developed a fatal outcome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fioravante da Silveira</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Health Science Center, Department of Clinical Medicine, Federal University of Santa Maria. leticiafdasilveira@live.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zago</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Health Science Center, Department of Clinical Medicine, Federal University of Santa Maria. aletheazago@yahoo.com.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zanchet</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Health Science Center, Department of Clinical Medicine, Federal University of Santa Maria. dlzanchet@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chemello</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Health Science Center, Department of Clinical Medicine, Federal University of Santa Maria; Department of Health Sciences, Federal University of Santa Maria . chemello.diego@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Reumatismo</MedlineTA><NlmUniqueID>0401302</NlmUniqueID><ISSNLinking>0048-7449</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051359" MajorTopicYN="Y">Lymphohistiocytosis, Hemophagocytic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055501" MajorTopicYN="Y">Macrophage Activation Syndrome</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>18</Day><Hour>13</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37462126</ArticleId><ArticleId IdType="doi">10.4081/reumatismo.2023.1597</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>